
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Lancet 2014;384:1577–1585.
113. Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet
therapy: a systematic review for the 2016 ACC/AHA Guideline Focused
Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary
Artery Disease: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol
2016;68:1116–1139.
114. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R. Should
duration of dual antiplatelet therapy depend on the type and/or potency of
implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet
treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Eur Heart J 2013;34:909–919.
115. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW,
Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L, DAPT Study
Investigators. Benefits and risks of extended dual antiplatelet therapy after
everolimus-eluting stents. JACC Cardiovasc Interv 2016;9:138–147.
116. Sharma A, Sharma SK, Vallakati A, Garg A, Lavie CJ, Mukherjee D, Marmur JD.
Duration of dual antiplatelet therapy after various drug-eluting stent implanta-
tion. Int J Cardiol 2016;215:157–166.
117. Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after
drug-eluting stent implantation: conceptual evolution based on emerging evi-
dence. Eur Heart J 2016;37:353–364.
118. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR,
Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C,
Stone GW, ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds
for coronary artery disease. N Engl J Med 2015;373:1905–1915.
119. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H,
Fusaro M, Kimura T, Kastrati A. Everolimus-eluting bioresorbable vascular scaf-
folds versus everolimus-eluting metallic stents: a meta-analysis of randomised
controlled trials. Lancet 2016;387:537–544.
120. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, Van Boven AJ,
Dominici M, Dudek D, McClean D, Helqvist S, Haude M, Reith S, de Sousa
Almeida M, Campo G, Iniguez A, Sabate M, Windecker S, Onuma Y.
Comparison of an everolimus-eluting bioresorbable scaffold with an
everolimus-eluting metallic stent for the treatment of coronary artery stenosis
(ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical
trial. Lancet 2016;388:2479–2491.
121. R
€
aber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T, Taniwaki M,
Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabate M, Windecker S.
Very late scaffold thrombosis: intracoronary imaging and histopathological and
spectroscopic findings. J Am Coll Cardiol 2015;66:1901–1914.
122. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-
Touchard A, Lopez-Minguez JR, Benedicto A, Masotti M, Zueco J, Iniguez A,
Velazquez M, Moreno R, Mainar V, Dominguez A, Pomar F, Melgares R, Rivero
F, Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C. A prospective
randomized trial of drug-eluting balloons versus everolimus-eluting stents in
patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized
clinical trial. J Am Col l Cardiol 2015;66:23–33.
123. Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao
Y, Ge J. A prospective, multicenter, randomized trial of paclitaxel-coated bal-
loon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-
stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv
2014;7:204–211.
124. Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro
M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S,
Kastrati A. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon
angioplasty in patients with restenosis after implantation of a drug-eluting stent
(ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013;381:461–467.
125. Wo¨ hrle J, Zadura M, Mobius-Winkler S, Leschke M, Opitz C, Ahmed W,
Barragan P, Simon JP, Cassel G, Scheller B. SeQuent Please World
Wide Registry: clinical results of SeQuent Please paclitaxel-coated balloon
angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol
2012;18:1733–1738.
126. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, Li X, Zhao X, Wang H, Zhao X,
Li X, Yu P, Zang H, Wang Z, Cao X, Zhang J, Pang W, Li J, Yang Y, Dangas GD.
Six versus 12 months of dual antiplatelet therapy after implantation of biode-
gradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-
IT 2 trial. Circ Cardiovasc Interv
2016;9:e003145.
127. Hong SJ, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Her AY, Kim YH, Jang Y,
Hong MK. 6-month versus 12-month dual-antiplatelet therapy following long
everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial.
JACC Cardiovasc Interv 2016;9:1438–1446.
128. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG,
Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S,
Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L,
Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy
duration following bare metal or drug-eluting coronary stents: the dual antipla-
telet therapy randomized clinical trial. JAMA 2015;313:1113–1121.
129. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J,
Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland
J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll
HP, Morice MC, LEADERS FREE Investigators. Polymer-free drug-coated coro-
nary stents in patients at high bleeding risk. N Engl J Med 2015;373:2038–2047.
130. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G,
Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga
E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P,
Briguori C, ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in
uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015;65:805–815.
131. Valgimigli M, Sabate M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius
S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-
chromium everolimus eluting stents or bare metal stent on fatal and non-fatal car-
diovascular events: patient level meta-analysis. BMJ 2014;349:g6427.
132. Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, Nilsen
DW, Klow NE, Uchto M, Trovik T, Bendz B, Stavnes S, Bjornerheim R, Larsen
AI, Slette M, Steigen T, Jakobsen OJ, Bleie O, Fossum E, Hanssen TA, Dahl-
Eriksen O, Njolstad I, Rasmussen K, Wilsgaard T, Nordrehaug JE, Norstent
Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N
Engl J Med 2016;375:1242–1252.
133. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger
B, Iniguez A, Gomez-Recio M, Masotti M, Velazquez MT, Sanchis J, Garcia-
Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A,
Mainar V, Lopez-Minguez JR, Moreu J, Marti V, Moreno R, Jimenez-Quevedo P,
Gonzalo N, Fernandez C, Macaya C. A randomized comparison of drug-eluting
balloon versus everolimus-eluting stent in patients with bare-metal stent-in-
stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal
Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol
2014;63:1378–1386.
134. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M,
Oktay S, Juni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S.
Report of a European Society of Cardiology-European Association of
Percutaneous Cardiovascular Interventions task force on the evaluation of cor-
onary stents in Europe: executive summary. Eur Heart J 2015;36:2608–2620.
135. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,
Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak
KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA,
Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA, CHARISMA Investigators. Patients
with prior myocardial infarction, stroke, or symptomatic peripheral arterial dis-
ease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982–1988.
136. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D,
Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC,
Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters
KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable
angina or non-ST-segment elevation myocardial infarction with or without
angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Lancet 2013;382:605–613.
137. Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS,
Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F,
Wilcox R, Morrow DA, TRA 2
P-TIMI 50 Steering Committee Investigators.
Vorapaxar for secondary prevention of thrombotic events for patients with
previous myocardial infarction: a prespecified subgroup analysis of the TRA
2
P-TIMI 50 trial. Lancet 2012;380:1317–1324.
138. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati
A. Periprocedural bleeding and 1-year outcome after percutaneous coronary
interventions: appropriateness of including bleeding as a component of a quad-
ruple end point. J Am Coll Cardiol 2008;51:690–697.
139. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T,
Budaj A, Goto S, Lopez-Sendon J, Diaz R, Dalby A, Van de Werf F, Ardissino
D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E,
Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from
P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights
from PEGASUS-TIMI 54. Eu r Heart J 2016;37:1133–1142.
140. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E,
Nicolau JC, Parkhomenko A, Lopez-Sendon J, Dellborg M, Dalby A, Spinar J,
Aylward P, Corbalan R, Abola MT, Jensen EC, Held P, Braunwald E, Sabatine
MS. Ticagrelor for prevention of ischemic events after myocardial infarction in
patients with peripheral artery disease. J Am Coll Cardiol 2016;67:2719–2728.
141. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW,
Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt
DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovas-
cular events in the subgroup of patients with previous myocardial infarction: a
collaborative meta-analysis of randomized trials. Eur Heart J 2016;37:390–399.
254b ESC Guidelines
Downloaded from https://academic.oup.com/eurheartj/article/39/3/213/4095043 by guest on 17 April 2022